Juvenile rheumatoid arthritis. Effects of disease activity and recombinant human growth hormone on insulin-like growth factor 1, insulin-like growth factor binding proteins 1 and 3, and osteocalcin.

OBJECTIVE To investigate possible mechanisms of growth impairment in children with juvenile rheumatoid arthritis (JRA). METHODS Eighteen prepubertal children with JRA and growth retardation received recombinant human growth hormone (rHuGH) for 1 year. Growth hormone profiles over 24 hours were obtained before treatment in 12 patients; the levels did not differ from those in "short normal" children. Levels of insulin-like growth factor 1 (IGF-1), IGF binding proteins (IGFBPs) 1 and 3, insulin, osteocalcin, and C-reactive protein (CRP), as well as the erythrocyte sedimentation rate were measured serially. Pretreatment levels were compared with control levels. RESULTS In JRA patients, IGF-1, IGFBP-3, and osteocalcin levels were significantly lower and insulin levels significantly higher than those in controls, but there was no significant difference in the level of IGFBP-1. With rHuGH treatment, height velocity and mean levels of IGF-1, osteocalcin, and insulin increased significantly, while mean levels of IGFBP-1 fell significantly. Levels of IGFBP-3 correlated with those of IGF-1. The height velocity correlated positively with IGF-1 and osteocalcin, and negatively with IGFBP-1. Levels of IGFBP-1 were inversely related to those of insulin and IGF-1. There was a significant negative correlation between the CRP and height velocity, IGF-1 level, and osteocalcin level. CONCLUSION IGF-1 production is impaired in children with active JRA. Treatment with a therapeutic dose of rHuGH can rectify the IGF-1 deficiency within 4 days, but its effect is adversely influenced by the acute-phase response, as reflected by an elevated CRP level.

[1]  M. Savage,et al.  The ‘dawn phenomenon’ in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin‐like growth factor binding protein‐1 , 1995, Clinical endocrinology.

[2]  S. Mohan,et al.  Evidence that human bone cells in culture secrete insulin‐like growth factor (IGF)‐II and IGF binding protein‐3 but not acid‐labile subunit both under basal and regulated conditions , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[3]  P. Woo,et al.  Inflammatory cytokine responses in juvenile chronic arthritis. , 1995, British journal of rheumatology.

[4]  G. Ciliberto,et al.  Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion. , 1994, The EMBO journal.

[5]  P. Woo,et al.  Treatment of growth retardation in juvenile chronic arthritis with recombinant human growth hormone. , 1994, The Journal of rheumatology.

[6]  P. Woo,et al.  Biochemical prediction of changes in spinal bone mass in juvenile chronic (or rheumatoid) arthritis treated with glucocorticoids. , 1993, The Journal of rheumatology.

[7]  W. Blum.  Insulin‐Like Growth Factors (IGFs) and IGF Binding Proteins in Chronic Renal Failure: Evidence for Reduced Secretion of IGFs , 1991, Acta paediatrica Scandinavica. Supplement.

[8]  A. Martini,et al.  Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[9]  D. Reid,et al.  Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: a relatively bone-sparing effect of deflazacort. , 1991, Pediatrics.

[10]  C. Cowell,et al.  Insulin-like growth factor and growth hormone secretion in juvenile chronic arthritis. , 1991, Annals of the rheumatic diseases.

[11]  J. Miell,et al.  Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin–like growth factor‐I , 1991, Clinical endocrinology.

[12]  T. Unterman,et al.  Multihormonal regulation of insulin-like growth factor-binding protein-1 in rat H4IIE hepatoma cells: the dominant role of insulin. , 1991, Endocrinology.

[13]  M. Ranke,et al.  Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients. , 1991, The Journal of clinical endocrinology and metabolism.

[14]  R. Baxter,et al.  Insulin‐Like Growth Factor (IGF) Binding Proteins: the Role of Serum IGFBPs in Regulating IGF Availability , 1991, Acta paediatrica Scandinavica. Supplement.

[15]  D. Clemmons,et al.  Insulin-dependent regulation of insulin-like growth factor-binding protein-1. , 1990, The Journal of clinical endocrinology and metabolism.

[16]  K. Mann,et al.  Relationship of glucocorticoid dosage to serum bone Gla-protein concentration in patients with rheumatologic disorders. , 1990, Arthritis and rheumatism.

[17]  C. Christiansen,et al.  Serum bone Gla protein: a potential marker of growth hormone (GH) deficiency and the response to GH therapy. , 1990, The Journal of clinical endocrinology and metabolism.

[18]  L. Mathews,et al.  Growth hormone regulation of the growth hormone receptor mRNA in cultured rat epiphyseal chondrocytes , 1990, Molecular and Cellular Endocrinology.

[19]  H. Zeisel,et al.  A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. , 1990, The Journal of clinical endocrinology and metabolism.

[20]  P. Hindmarsh,et al.  Dose-response curves for treatment with biosynthetic human growth hormone. , 1990, Journal of Endocrinology.

[21]  B. Carlsson,et al.  Regulation by GH of insulin-like growth factor-I mRNA expression in rat epiphyseal growth plate as studied with in-situ hybridization. , 1990, The Journal of endocrinology.

[22]  C. Langman,et al.  Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. , 1990, The Journal of pediatrics.

[23]  D. Dunger,et al.  THE GROWTH HORMONE INDEPENDENT INSULIN‐LIKE GROWTH FACTOR‐I BINDING PROTEIN BP‐28 IS ASSOCIATED WITH SERUM INSULIN‐LIKE GROWTH FACTOR‐I INHIBITORY BIOACTIVITY IN ADOLESCENT INSULIN‐DEPENDENT DIABETICS , 1990, Clinical endocrinology.

[24]  T. Aitman,et al.  Serum IGF-I levels and growth failure in juvenile chronic arthritis. , 1989, Clinical and experimental rheumatology.

[25]  M. Preece,et al.  A monoclonal antibody to human insulin-like growth factor-I: characterization, use in radioimmunoassay and effect on the biological activities of the growth factor. , 1989, Journal of molecular endocrinology.

[26]  R. Graham,et al.  Actions of recombinant human γ-interferon and tumor necrosis factor α on the proliferation and osteoblastic characteristics of human trabecular bone cells in vitro , 1988 .

[27]  M. Lange,et al.  Insulinlike growth factor 1 production is inhibited in human sepsis. , 1988, Archives of surgery.

[28]  N. Skakkebaek,et al.  Serum bone Gla-protein as a marker of bone growth in children and adolescents: correlation with age, height, serum insulin-like growth factor I, and serum testosterone. , 1988, The Journal of clinical endocrinology and metabolism.

[29]  S. Chernausek,et al.  Discordance of serum and tissue somatomedin levels in growth hormone-stimulated growth in the rat. , 1988, Endocrinology.

[30]  P. Hindmarsh,et al.  Relation between height velocity and fasting insulin concentrations. , 1988, Archives of disease in childhood.

[31]  E. Silverman,et al.  Insulin-like growth factors I and II in children with systemic onset juvenile arthritis. , 1988, The Journal of rheumatology.

[32]  R. Hällgren,et al.  The acute effect of high dose corticosteroid treatment on serum osteocalcin. , 1988, Metabolism: clinical and experimental.

[33]  C. Cowell,et al.  Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma. , 1987, The Journal of clinical endocrinology and metabolism.

[34]  Z. Laron,et al.  INSULIN‐LIKE GROWTH FACTOR I (IGF‐I) IN HEALTHY CHILDREN, ADOLESCENTS AND ADULTS AS DETERMINED BY A RADIOIMMUNOASSAY SPECIFIC FOR THE SYNTHETIC 53–70 PEPTIDE REGION , 1986, Clinical endocrinology.

[35]  L. Phillips,et al.  Glucocorticoid effects on somatomedins and somatomedin inhibitors. , 1985, The Journal of clinical endocrinology and metabolism.

[36]  M. Kutner,et al.  The Short Child with Subnormal Plasma Somatomedin C , 1985, Pediatric Research.

[37]  K. Hall,et al.  Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. , 1984, Acta endocrinologica.

[38]  A. Stiles,et al.  Tissue concentrations of somatomedin C: further evidence for multiple sites of synthesis and paracrine or autocrine mechanisms of action. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Poser,et al.  Production of osteocalcin by human bone cells in vitro. Effects of 1,25(OH)2D3, 24,25(OH)2D3, parathyroid hormone, and glucocorticoids. , 1984, Metabolic bone disease & related research.

[40]  R. Russell,et al.  An interleukin 1 like factor stimulates bone resorption in vitro , 1983, Nature.

[41]  D. Cameron,et al.  Gonadal dysfunction in the spontaneously diabetic BB rat. , 1983, Metabolism: clinical and experimental.

[42]  J. Jansson,et al.  Growth hormone stimulates longitudinal bone growth directly. , 1982, Science.

[43]  A. Klibanski,et al.  Reduction of plasma immunoreactive somatomedin C during fasting in humans. , 1981, The Journal of clinical endocrinology and metabolism.

[44]  P. Price,et al.  Radioimmunoassay for the vitamin K-dependent protein of bone and its discovery in plasma. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[45]  B. Bernstein,et al.  Hip joint restoration in juvenile rheumatoid arthritis. , 1977, Arthritis and rheumatism.

[46]  B. Bernstein,et al.  Growth retardation in juvenile rheumatoid arthritis (JRA). , 1977, Arthritis and rheumatism.

[47]  J. V. Van Wyk,et al.  Serum somatomedin-C in hypopituitarism and in other disorders of growth. , 1977, The Journal of pediatrics.

[48]  Ansell Bm,et al.  Alternate-day corticosteroid therapy in juvenile chronic polyarthritis. , 1974 .

[49]  B. Ansell,et al.  Growth in Still's Disease , 1956, Lancet.

[50]  B. Ansell,et al.  Cortisol and Growth Hormone Secretion in Relation to Linear Growth: Patients with Still's Disease on Different Therapeutic Regimens , 1970, British medical journal.